Other languages Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-29 EDT			5-day change	1st Jan Change
17.05 ^USD	+5.44%		+13.06%	+55.85%

04-23	Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	MT
04-22	RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy	04-15
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	03-28
Edgewise Therapeutics Full Year 2023 Net Loss Widens	02-22
Edgewise Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22
Edgewise Therapeutics Drug Candidate to Treat Duchenne Gets FDA's Fast Track Designation	02-13
Edgewise Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy	02-13
Edgewise Therapeutics Insider Sold Shares Worth $596,805, According to a Recent SEC Filing	02-09
Edgewise Therapeutics Insider Sold Shares Worth $1,419,759, According to a Recent SEC Filing	01-25
Edgewise Therapeutics Insider Bought Shares Worth $4,999,995, According to a Recent SEC Filing	01-25
Top Midday Gainers	01-19
Edgewise Therapeutics Surging After Pricing $240 Million Stock Sale Above Last Close	01-19
Edgewise Therapeutics Insider Sold Shares Worth $1,610,097, According to a Recent SEC Filing	12-28
Edgewise Says US FDA Grants Orphan Drug, Rare Pediatric Disease Designations for Investigational Muscular Dystrophy Therapy	11-30
Edgewise Therapeutics, Inc. Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA	11-30
Edgewise Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Edgewise Therapeutics Expands Duchenne Muscular Dystrophy Clinical Program	23-10-26
Edgewise Therapeutics Announces Expansion of Their Edg-5506 Clinical Program in Duchenne Muscular Dystrophy	23-10-26
Edgewise Therapeutics, Inc. Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy	23-09-26
Edgewise Therapeutics, Inc. Begins Dosing First-In-Human Phase 1 Trial of EDG-7500	23-09-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Other languages

Filters